Cancer of the pancreas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Malvezzi, 2014, European cancer mortality predictions for the year 2014, Ann Oncol, 25, 1650, 10.1093/annonc/mdu138

Yeo, 2015, Demographics, epidemiology, and inheritance of pancreatic ductal adenocarcinoma, Semin Oncol, 42, 8, 10.1053/j.seminoncol.2014.12.002

Larsson, 2012, Red and processed meat consumption and risk of pancreatic cancer: meta-analysis of prospective studies, Br J Cancer, 106, 603, 10.1038/bjc.2011.585

Ojajarvi, 2000, Occupational exposures and pancreatic cancer: a meta-analysis, Occup Environ Med, 57, 316, 10.1136/oem.57.5.316

Maisonneuve, 2015, Risk factors for pancreatic cancer: a summary review of meta-analytical studies, Int J Epidemiol, 44, 186, 10.1093/ije/dyu240

Rishi, 2015, Pathological and molecular evaluation of pancreatic neoplasms, Semin Oncol, 42, 28, 10.1053/j.seminoncol.2014.12.004

Wisnoski, 2008, 672 patients with acinar cell carcinoma of the pancreas: a population-based comparison to pancreatic adenocarcinoma, Surgery, 144, 141, 10.1016/j.surg.2008.03.006

Dudeja, 2015, Premalignant cystic neoplasms of the pancreas, Semin Oncol, 42, 70, 10.1053/j.seminoncol.2014.12.007

Esposito, 2014, Pathology of pancreatic ductal adenocarcinoma: facts, challenges and future developments, World J Gastroenterol, 20, 13833, 10.3748/wjg.v20.i38.13833

Waddell, 2015, Whole genomes redefine the mutational landscape of pancreatic cancer, Nature, 518, 495, 10.1038/nature14169

Nawaz, 2013, Performance characteristics of endoscopic ultrasound in the staging of pancreatic cancer: a meta-analysis, JOP, 14, 484

Al-Hawary, 2014, Pancreatic ductal adenocarcinoma radiology reporting template: consensus statement of the Society of Abdominal Radiology and the American Pancreatic Association, Radiology, 270, 248, 10.1148/radiol.13131184

Bipat, 2005, Ultrasonography, computed tomography and magnetic resonance imaging for diagnosis and determining resectability of pancreatic adenocarcinoma: a meta-analysis, J Comput Assist Tomogr, 29, 438, 10.1097/01.rct.0000164513.23407.b3

Callery, 2009, Pretreatment assessment of resectable and borderline resectable pancreatic cancer: expert consensus statement, Ann Surg Oncol, 16, 1727, 10.1245/s10434-009-0408-6

Wong, 2008, Staging of pancreatic adenocarcinoma by imaging studies, Clin Gastroenterol Hepatol, 6, 1301, 10.1016/j.cgh.2008.09.014

Ngamruengphong, 2015, Preoperative endoscopic ultrasound-guided fine needle aspiration does not impair survival of patients with resected pancreatic cancer, Gut, 64, 1105, 10.1136/gutjnl-2014-307475

Abrams, 2009, Combined modality treatment of resectable and borderline resectable pancreas cancer: expert consensus statement, Ann Surg Oncol, 16, 1751, 10.1245/s10434-009-0413-9

Bockhorn, 2014, Borderline resectable pancreatic cancer: a consensus statement by the International Study Group of Pancreatic Surgery (ISGPS), Surgery, 155, 977, 10.1016/j.surg.2014.02.001

National Comprehensive Cancer Network. NCCN Guidelines Version 2.2015 Pancreatic Adenocarcinoma. http://www.nccn.org.

Delpero, 2014, Pancreaticoduodenectomy for pancreatic ductal adenocarcinoma: a French multicentre prospective evaluation of resection margins in 150 evaluable specimens, HPB (Oxford), 16, 20, 10.1111/hpb.12061

Delpero, 2015, Pancreatic adenocarcinoma with venous involvement: is up-front synchronous portal-superior mesenteric vein resection still justified? A survey of the association francaise de chirurgie, Ann Surg Oncol, 22, 1874, 10.1245/s10434-014-4304-3

Mitchem, 2012, Long-term results of resection of adenocarcinoma of the body and tail of the pancreas using radical antegrade modular pancreatosplenectomy procedure, J Am Coll Surg, 214, 46, 10.1016/j.jamcollsurg.2011.10.008

Kooby, 2010, A multicenter analysis of distal pancreatectomy for adenocarcinoma: is laparoscopic resection appropriate?, J Am Coll Surg, 210, 779, 10.1016/j.jamcollsurg.2009.12.033

Ricci, 2015, Laparoscopic versus open distal pancreatectomy for ductal adenocarcinoma: a systematic review and meta-analysis, J Gastrointest Surg, 19, 770, 10.1007/s11605-014-2721-z

Tol, 2014, Definition of a standard lymphadenectomy in surgery for pancreatic ductal adenocarcinoma: a consensus statement by the International Study Group on Pancreatic Surgery (ISGPS), Surgery, 156, 591, 10.1016/j.surg.2014.06.016

Ragulin-Coyne, 2012, Perioperative mortality after pancreatectomy: a risk score to aid decision-making, Surgery, 152, S120, 10.1016/j.surg.2012.05.018

van der Gaag, 2010, Preoperative biliary drainage for cancer of the head of the pancreas, N Engl J Med, 362, 129, 10.1056/NEJMoa0903230

Neoptolemos, 2001, Adjuvant chemoradiotherapy and chemotherapy in resectable pancreatic cancer: a randomised controlled trial, Lancet, 358, 1576, 10.1016/S0140-6736(01)06651-X

Oettle, 2007, Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial, JAMA, 297, 267, 10.1001/jama.297.3.267

Neoptolemos, 2010, Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trial, JAMA, 304, 1073, 10.1001/jama.2010.1275

Marechal, 2012, Levels of gemcitabine transport and metabolism proteins predict survival times of patients treated with gemcitabine for pancreatic adenocarcinoma, Gastroenterology, 143, 664, 10.1053/j.gastro.2012.06.006

Assifi, 2011, Neoadjuvant therapy in pancreatic adenocarcinoma: a meta-analysis of phase II trials, Surgery, 150, 466, 10.1016/j.surg.2011.07.006

Gillen, 2010, Preoperative/neoadjuvant therapy in pancreatic cancer: a systematic review and meta-analysis of response and resection percentages, PLoS Med, 7, e1000267, 10.1371/journal.pmed.1000267

Denost, 2013, Pancreaticoduodenectomy following chemoradiotherapy for locally advanced adenocarcinoma of the pancreatic head, HPB (Oxford), 15, 716, 10.1111/hpb.12039

Landry, 2010, Randomized phase II study of gemcitabine plus radiotherapy versus gemcitabine, 5-fluorouracil, and cisplatin followed by radiotherapy and 5-fluorouracil for patients with locally advanced, potentially resectable pancreatic adenocarcinoma, J Surg Oncol, 101, 587, 10.1002/jso.21527

Hammel, 2013, Comparison of chemoradiotherapy (CRT) and chemotherapy (CT) in patients with a locally advanced pancreatic cancer (LAPC) controlled after 4 months of gemcitabine with or without erlotinib: Final results of the international phase III LAP 07 study, J Clin Oncol, 31

Shinchi, 2002, Length and quality of survival after external-beam radiotherapy with concurrent continuous 5-fluorouracil infusion for locally unresectable pancreatic cancer, Int J Radiat Oncol Biol Phys, 53, 146, 10.1016/S0360-3016(01)02806-1

Sultana, 2007, Systematic review, including meta-analyses, on the management of locally advanced pancreatic cancer using radiation/combined modality therapy, Br J Cancer, 96, 1183, 10.1038/sj.bjc.6603719

Chauffert, 2006, Phase III trial comparing initial chemoradiotherapy (intermittent cisplatin and infusional 5-FU) followed by gemcitabine vs. gemcitabine alone in patients with locally advanced non-metastatic pancreatic cancer: a FFCD-SFRO study, J Clin Oncol, 24

Loehrer, 2011, Gemcitabine alone versus gemcitabine plus radiotherapy in patients with locally advanced pancreatic cancer: an Eastern Cooperative Oncology Group trial, J Clin Oncol, 29, 4105, 10.1200/JCO.2011.34.8904

Mukherjee, 2013, Gemcitabine-based or capecitabine-based chemoradiotherapy for locally advanced pancreatic cancer (SCALOP): a multicentre, randomised, phase 2 trial, Lancet Oncol, 14, 317, 10.1016/S1470-2045(13)70021-4

Stark, 2015, Endoscopic and operative palliation strategies for pancreatic ductal adenocarcinoma, Semin Oncol, 42, 163, 10.1053/j.seminoncol.2014.12.014

Ripamonti, 2012, Management of cancer pain: ESMO Clinical Practice Guidelines, Ann Oncol, 23, vii139, 10.1093/annonc/mds233

Burris, 1997, Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial, J Clin Oncol, 15, 2403, 10.1200/JCO.1997.15.6.2403

Ciliberto, 2013, Role of gemcitabine-based combination therapy in the management of advanced pancreatic cancer: a meta-analysis of randomised trials, Eur J Cancer, 49, 593, 10.1016/j.ejca.2012.08.019

Moore, 2007, Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group, J Clin Oncol, 25, 1960, 10.1200/JCO.2006.07.9525

Conroy, 2011, FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer, N Engl J Med, 364, 1817, 10.1056/NEJMoa1011923

Von Hoff, 2014, Albumin-bound paclitaxel plus gemcitabine in pancreatic cancer, N Engl J Med, 370, 479

Oettle, 2014, Second-line oxaliplatin, folinic acid, and fluorouracil versus folinic acid and fluorouracil alone for gemcitabine-refractory pancreatic cancer: outcomes from the CONKO-003 trial, J Clin Oncol, 32, 2423, 10.1200/JCO.2013.53.6995

Sonnenblick, 2011, Complete remission, in BRCA2 mutation carrier with metastatic pancreatic adenocarcinoma, treated with cisplatin based therapy, Cancer Biol Ther, 12, 165, 10.4161/cbt.12.3.16292

Chmielecki, 2014, Comprehensive genomic profiling of pancreatic acinar cell carcinomas identifies recurrent RAF fusions and frequent inactivation of DNA repair genes, Cancer Discov, 4, 1398, 10.1158/2159-8290.CD-14-0617

Yachida, 2010, Distant metastasis occurs late during the genetic evolution of pancreatic cancer, Nature, 467, 1114, 10.1038/nature09515

Blackford, 2009, SMAD4 gene mutations are associated with poor prognosis in pancreatic cancer, Clin Cancer Res, 15, 4674, 10.1158/1078-0432.CCR-09-0227

Klumpen, 2011, mTOR inhibitor treatment of pancreatic cancer in a patient with Peutz-Jeghers syndrome, J Clin Oncol, 29, e150, 10.1200/JCO.2010.32.7825

Hidalgo, 2009, The hedgehog pathway and pancreatic cancer, N Engl J Med, 361, 2094, 10.1056/NEJMcibr0905857

Greenhalf, 2014, Pancreatic cancer hENT1 expression and survival from gemcitabine in patients from the ESPAC-3 trial, J Natl Cancer Inst, 106, djt347, 10.1093/jnci/djt347

Ormanns, 2014, pERK, pAKT and p53 as tissue biomarkers in erlotinib-treated patients with advanced pancreatic cancer: a translational subgroup analysis from AIO-PK0104, BMC Cancer, 14, 624, 10.1186/1471-2407-14-624

Dykewicz, 2001, Summary of the guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients, Clin Infect Dis, 33, 139, 10.1086/321805